Biogen: BeNeLuxA Spinraza Talks “Collaborative And Constructive" But Not Without Challenges
Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.
You may also be interested in...
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.
Francis Arickx from the cross-country coalition BeNeLuxA spoke this month about how the initiative had delivered proof of concept and discussed why uniting across borders is important for delivering access to transformative but expensive medicines.